Wall Street Zen Upgrades Aclarion (NASDAQ:ACON) to Hold

Aclarion (NASDAQ:ACON) was upgraded by research analysts at Wall Street Zen to a “hold” rating in a report released on Saturday.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Aclarion in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of “Sell”.

Aclarion Stock Performance

Shares of ACON opened at $5.39 on Friday. Aclarion has a 52 week low of $5.02 and a 52 week high of $3,499.51. The stock has a market capitalization of $3.61 million, a price-to-earnings ratio of -0.36 and a beta of 1.43. The stock has a fifty day moving average of $6.68 and a 200-day moving average of $7.24.

Aclarion (NASDAQ:ACON) last issued its earnings results on Wednesday, November 12th. The company reported ($2.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.64) by ($0.29). The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.02 million. Aclarion had a negative return on equity of 67.53% and a negative net margin of 10,908.50%. As a group, equities analysts forecast that Aclarion will post -263.33 EPS for the current year.

Aclarion Company Profile

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.